~~<i id='CE452BAD2E'><strike id='CE452BAD2E'><tt id='CE452BAD2E'><pre id='CE452BAD2E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：comprehensive 2025-09-03 12:06:55 - browse：23

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Streamlined flu vaccines recommended by FDA advisory panel

focus

knowledge

Wikipedia

focus

knowledge

SharissaDerricottoutsideofherparents’homeinLawton,Okla.NickOxfordforKHNForyears,SharissaDerricott,30

WSS

Canadians with cystic fibrosis outlive Americans by a decade

Longer MASH drug regimen improved liver, Akero study finds

Dexcom's push to bring CGM to type 2 diabetes patients

Readout Newsletter: BridgeBio, Akero, and human embryo models

Ozempic has benefits for kidney disease as well as diabetes

State of the Union pitch: Bigger Medicare drug price negotiations

knowledge

entertainment

focus

Medicare proposal to cover medical devices draws a mixed reaction

The biotech scorecard for Q3: 15 stock

Medical leaders decry Supreme Court decision on affirmative action

The public health thinking behind the CDC’s new Covid guidance

Medicare proposal to cover medical devices draws a mixed reaction

The public health thinking behind the CDC’s new Covid guidance

Virginia high school admissions case could be legal follow

What affirmative action's end means to a medical student

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

knowledge

Medicare drug price negotiation continues, as pharma counteroffers

Change Healthcare: What is it, why does its cyberattack matter?

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Medicare drug price negotiation hearing pits pharma v Biden admin

Security flaws in third

The wait for US passports is creating travel purgatory and snarling summer plans

Wikipedia

Wikipedia

focus

knowledge